A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 12, 2017

Primary Completion Date

November 5, 2017

Study Completion Date

December 5, 2017

Conditions
Dermatitis, AtopicDermatitis EczemaDermatitis, Eczematous
Interventions
DRUG

ASN002

Daily dose of ASN002 for 28 days

DRUG

Placebo Oral Tablet

Placebo for ASN002 for 28 days

Trial Locations (10)

23507

Virginia Clinical Research, Inc., Norfolk

30045

Dermatology Research Associates, Los Angeles

33609

Olympian Clinical Research, Tampa

33624

Forward Clinical Trials, Inc., Tampa

40241

Dermatology Specialists Research, Louisville

77004

Center for Clinical Studies, Ltd., LLP, Houston

78229

Progressive Clinical Research, P.A., San Antonio

92123

TCR Medical Corporation, San Diego

94538

Center for Dermatology Clinical Research, Inc., Fremont

Unknown

Innovaderm Research, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Asana BioSciences

INDUSTRY